NBIX241220C230000
- 0.00
- 0.000.00%
Neurocrine Biosciences Newsroom
Neurocrine Biosciences Rises on FDA Nod for CAH Drug
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
TD Cowen Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
CCORF Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $167
Wedbush Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $148
Express News | Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target
Wedbush Reaffirms Their Buy Rating on Neurocrine (NBIX)
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $160 to $190
Neurocrine Price Target Maintained With a $190.00/Share by HC Wainwright & Co.
Neurocrine Biosciences Analyst Ratings
TD Cowen Sticks to Their Buy Rating for Neurocrine (NBIX)
Reported Friday, Neurocrine Biosciences' CRENESSITY Receives FDA Approval, Revolutionizing Treatment For Classic Congenital Adrenal Hyperplasia
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating
Express News | Neurocrine Biosciences Inc - Crenessity Expected to Be Available in One Week
Express News | FDA: Crenessity Approved as Adjunctive Treatment for Adults & Pediatric Patients 4 Years of Age & Older With Classic Congenital Adrenal Hyperplasia
Express News | FDA Approves Neurocrine Biosciences' Crenessity- Website
FDA Approves New Treatment for Congenital Adrenal Hyperplasia
"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman
Investors in Neurocrine Biosciences (NASDAQ:NBIX) Have Seen Notable Returns of 53% Over the Past Three Years
Neurocrine Biosciences To Present At Evercore HealthCONx Conference; Webcast At 10:50 AM ET